This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by HELFER, E. L. Articles by ROSE, L. I. Search for Related Content PubMed PubMed Citation Articles by HELFER, E. L. Articles by ROSE, L. I.

Side-Effects of Spironolactone Therapy in the Hirsute Woman

Division of Endocrinology and Metabolism, Department of Medicine, Hahnemann University School of Medicine Philadelphia, Pennsylvania 19102

Address requests for reprints to: Leslie I. Rose, M.D., Hahnemann University School of Medicine, 230 North Broad Street, Mail Stop 426, Philadelphia, Pennsylvania 19102.

Spironolactone, an aldosterone antagonist with antiandrogenic activities, is often used to treat hirsute women. Several investigators have reported beneficial effects of such treatment, but the dosages used and side-effects encountered differ in their reports. To clarify this issue, 26 consecutive premenopausal women with idiopathic hirsutism were prospectively evaluated during spironolactone treatment. Sixteen women initially received 100 mg spironolactone twice daily on days 4–21 of their menstrual cycles. In 11 women (68%), the dosage had to be decreased or the medication discontinued due to side-effects. The major side-effect, metrorrhagia with 14-day cycles, occurred in 9 women (56%). This side-effect, while not dangerous, was intolerable to these women. In one woman, spironolactone was discontinued because of urticaria and in another because of scalp hair loss. Ten women initially received 50 mg spironolactone twice daily on days 4–21 of their menstrual cycles. Two developed metrorrhagia, but no other side-effects were noted. Because of the incidence of metrorrhagia at higher dosages, we recommend that spironolactone be administered cyclically at a starting dosage of 50 mg twice daily on days 4–21 of the menstrual cycle. Alternatively, one may consider adding cyclical estrogen/progesterone therapy to continuous spironolactone therapy

Received June 13, 1987.

This article has been cited by other articles:

				M. A. Ganie, M. L. Khurana, M. Eunice, M. Gulati, S. N. Dwivedi, and A. C. Ammini Comparison of Efficacy of Spironolactone with Metformin in the Management of Polycystic Ovary Syndrome: An Open-Labeled Study J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2756 - 2762. [Abstract] [Full Text] [PDF]

				M. Epstein Aldosterone receptor blockade and the role of eplerenone: evolving perspectives Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1984 - 1992. [Full Text] [PDF]

				M. Epstein Aldosterone as a determinant of cardiovascular and renal dysfunction J R Soc Med, January 8, 2001; 94(8): 378 - 383. [Full Text] [PDF]

				R. Azziz, E. Carmina, and M. E. Sawaya Idiopathic Hirsutism Endocr. Rev., August 1, 2000; 21(4): 347 - 362. [Abstract] [Full Text] [PDF]